$1.76
-0.065-3.55%
Last update: Oct 23, 12:43 PM
Alector Inc (ALEC) Stock Price, Quote, News & History
ALECNASDAQ
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.
You can purchase shares of Alector (NASDAQ:ALEC) through any online brokerage.
Other companies in Alector’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Alector has a consensus price target of $5.56.
The stock price for Alector (NASDAQ: ALEC) is $1.765 last updated October 23, 2026 at 12:43 PM EDT.
There are no upcoming dividends for Alector.
Alector does not have any upcoming earnings scheduled.
There is no upcoming split for Alector.
Alector is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for...
